Which patient- and physician-related factors are associated with guideline adherent initiation of adjuvant endocrine therapy? Results of the prospective multi-centre cohort study BRENDA II
We analysed factors that might influence patients’ and physicians’ decisions against the initiation of guideline adherent adjuvant endocrine therapy (ET).
In a prospective multi-centre study, including four certified breast cancer centres in Germany, patients with primary breast cancer were included from 2009 to 2012. Patients completed a questionnaire prior to surgery, adjuvant therapy, and 6 months after adjuvant therapy. This questionnaire assessed health-related quality of life (QoL), psychiatric co-morbidity, demographic characteristics, and the intensity of fear for ET. Guideline adherence was classified based on an algorithm derived from international guidelines. The tumour board’s (TB) decisions against or for ET was documented. The TB was blinded regarding the guideline results.
In 666 patients, adjuvant ET was indicated according to the guideline recommendations. The TB decided in 92.3 % (n = 615) of those that adjuvant ET was indicated. TB’s decision against ET was associated with the younger age of patients (OR = 0.5; 95 % CI 0.3–0.9) and poor QoL (OR = 1.7; 95 % CI 1.0–2.8). In 93 patients, ET was not indicated according to the guidelines, and the TB decided in 84 of those not to prescribe ET. The TB decided in 93.4 % of the cases according to the guidelines. Of the patients, where the TB prescribed ET, 5 % (n = 31) decided against ET. This decision was associated with fear of ET (OR = 2.2; 95 % CI 1.0–5.2) and higher age (OR 9; 95 % CI 1.0–48.1). Psychiatric co-morbidity (OR = 1.8; 95 % CI 0.7–4.2), poor QoL (OR = 0.4; 95 % CI 0.2–1.2), and education (OR = 1.2; 95 % CI 0.5–2.6) were not associated with the decision.
Guideline adherent implementation of adjuvant ET is high. Physicians’ decision against ET is mainly associated with patients’ younger age and poor quality of life, whereas patients’ decision, once the TB decided to initiate ET and if ET is indicated by guidelines, is associated with higher age and fear of ET.
KeywordsBreast cancer Guideline Endocrine therapy
Compliance with ethical standards
Conflict of interest
All authors declare that there are no potential conflicts of interest, including financial, personal, or relationship with other people or organizations that could inappropriately influence this work.
Parts of this work were supported by the German Federal Ministry of Education and Research (BMBF-Grant-01ZP0505).
This study and the BRENDA project have been approved by the ethics committee of the University of Ulm.
- 1.RKI, Breast cancer incidence, Germany. 2014, Robert-Koch-Institute, Tumor Registry.Google Scholar
- 6.Schwentner L, Van Ewijk R, Kühn T, Flock F, Felberbaum R, Blettner M, Kreienberg R, Janni W, Wöckel A, Singer S. Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II. Support Care Cancer. 2016;24(6):2759–66. doi: 10.1007/s00520-016-3088-3.CrossRefPubMedGoogle Scholar
- 8.Löwe BSR, Zipfel S, Herzog W. PHQ-D Gesundheitsfragebogen für Patienten. Manual. Karlsruhe: Pfizer; 2002.Google Scholar
- 13.Kreienberg R, Kopp I, Albert U. Interdisciplinary S3 guideline for diagnosis and therapy of breast cancer in women. German cancer society, 2008.Google Scholar
- 16.Wolters R, et al. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. Breast Cancer Res Treat. 2013;142(3):579–90.CrossRefPubMedGoogle Scholar
- 19.Untch M, et al. 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus—opinion of a german team of experts (zurich 2013). Breast Care (Basel). 2013;8(3):221–9.Google Scholar
- 21.Gray R. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013; 31(suppl; abstract 5).Google Scholar
- 26.Hadji P, et al. The Patient’s Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. 2013;24(6):1505–12.CrossRefPubMedGoogle Scholar
- 28.Neven P, et al. The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast. 2014;23(4):393–9.CrossRefPubMedGoogle Scholar